Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification [1]

AIDS

Volumn 21, Issue 13, 2007, Pages 1829-1830

  Martínez, Esteban ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LETTER; LOG RANK TEST; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 34547804397     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328133f081     Document Type: Letter

References (9)

1. Abgrall S, Yeni PG, Bouchaud O, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database on HIV. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. AIDS 2006; 20:2099-2106.
2. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, et al., on behalf of the Euro SIDA study group. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15:2385-2395.
3. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al., for the NEFA Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
4. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of HIV infection. The European Medicines Agency. London, 17 February 2005. Available at: www.emea.eu.int/pdfs/human/ewp/063302en.pdf. Accessed: 3 December 2006.
5. Phillips AN, Walker AS. Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18:365-370.
6. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. AIDS 2007; 21:367-369.
7. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity. II: Observational studies. Lancet 2001; 357:455-462.
8. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M, for the EuroSIDA, the French Hospital Database on HIV, and the Swiss Cohort Study Groups. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999; 13:2075-2082.
9. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342:1907-1909.